

US00D892151S

(12) **United States Design Patent** (10) **Patent No.:** **US D892,151 S**
Pontious (45) **Date of Patent:** **** *Aug. 4, 2020**

- (54) **DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACE** 8,041,714 B2 * 10/2011 Aymeloglu G06F 16/248
707/726
8,057,291 B2 * 11/2011 Ng A63F 13/12
463/9
- (71) Applicant: **NANTHEALTH, INC.**, Culver City, CA (US) D675,639 S 2/2013 Anzures et al.
D676,864 S 2/2013 Velasco et al.
D687,047 S 7/2013 Hales, IV et al.
- (72) Inventor: **Corey L. Pontious**, Warwick, RI (US) D694,259 S * 11/2013 Klein D14/486
D696,681 S * 12/2013 Kim D14/486
- (73) Assignee: **NANTHEALTH, INC.**, Culver City, CA (US) 8,605,094 B1 * 12/2013 Alfaro G06T 11/60
345/440
9,128,995 B1 * 9/2015 Fletcher G06F 16/248
D757,032 S * 5/2016 Sabia D14/485
D757,764 S * 5/2016 Han D14/486
- (*) Notice: This patent is subject to a terminal disclaimer. (Continued)

(**) Term: **15 Years**

OTHER PUBLICATIONS

- (21) Appl. No.: **29/649,132**
- (22) Filed: **May 25, 2018**
- (51) **LOC (12) Cl.** **14-04**
- (52) **U.S. Cl.**
USPC **D14/486**
- (58) **Field of Classification Search**
USPC D14/485-495
CPC G06F 3/048; G06F 3/0481; G06F 3/04817;
G06F 3/0482; G06F 3/0483; G06F
3/04842; G06F 3/0485; G06F 3/04855;
G06F 3/0486; G06F 3/0488; G06F
3/04886; G06F 9/4443; G06F 17/211;
G06F 17/212

Naithani, Sushma, "OMICs Data Analysis Tool" Oct. 2016, ResearchGate, site visited Mar. 4, 2020: https://www.researchgate.net/figure/Plant-Reactome-pathway-analysis-tools-interface-OMICs-data-analysis-A-The-analysis_fig4_309571296 (Year: 2016).*

(Continued)

Primary Examiner — Jack Reickel
(74) *Attorney, Agent, or Firm* — Stetina Brunda Garred and Brucker

(57) **CLAIM**

The ornamental design for a display screen or portion thereof with graphical user interface, as shown and described.

DESCRIPTION

(56) **References Cited**

U.S. PATENT DOCUMENTS

D507,798 S *	7/2005	Jewitt	D14/486
D509,830 S *	9/2005	Liu	D14/486
D553,630 S *	10/2007	Blencowe	D14/486
D569,869 S *	5/2008	Chotai	D14/485
D599,372 S	9/2009	Pelczarski et al.		
D599,377 S *	9/2009	Jewitt	D14/489
D601,169 S *	9/2009	LaManna	D14/492

FIG. 1 is a front view of a display screen or portion thereof with graphical user interface showing the new design; and, FIG. 2 is a front view of a second embodiment thereof. The broken lines showing the display screen and various features of the graphical user interface are included for the purpose of illustrating environment of the claimed design. The broken lines form no part of the claimed design.

1 Claim, 2 Drawing Sheets

Treatment Options Sample Hospital

All (10) ENDORSED(8) OMICS-GUIDED (2) G. WCA TRIALS (7) Order ID: 80808

Cancer Type: Pathology: Stage: Site of Treatment: Goal:

Performance Status: Adult/Pediatric: MRI Level: X-ray: H-ras Gene:

BRCA1 Gene: ERCC1 Protein: TOP2A Protein:

Select a treatment, and then select Save to list this treatment to the patient. Modify your search using the filters above. ✔ Support ✖ Opposition — None

REGIMEN NAME	ENDORSED REGIMEN	OMICS GUIDANCE	OMICS JUSTIFICATION	LEVEL OF EVIDENCE	UNSELECTED OUTCOME	ESTIMATED COST
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FLU/LEO)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of TOP2A has been associated with improved response to irinotecan.	A4	Median OS: 28.7 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FLU/LEO) and Oxaliplatin	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of TOP2A has been associated with improved response to irinotecan.	A4	Median OS: 25.8 months	\$0,000.00
<input type="checkbox"/> Capecitabine	<input checked="" type="checkbox"/>	<input type="checkbox"/>	N/A	A4	Median OS: 13.2 months	\$0,000.00
<input type="checkbox"/> Capecitabine and Bevacizumab	<input checked="" type="checkbox"/>	<input type="checkbox"/>	N/A	B1	Median OS: 15.6 months	\$0,000.00
<input type="checkbox"/> Gemigli	<input type="checkbox"/>	<input checked="" type="checkbox"/>	BRCA1 del in prostate and ovarian cancer (yes)	N/A	N/A	\$0,000.00
<input type="checkbox"/> Rutepranib	<input type="checkbox"/>	<input checked="" type="checkbox"/>	BRCA1 del in ovarian cancer (yes)	N/A	N/A	\$0,000.00
<input type="checkbox"/> Capecitabine and Oxaliplatin	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A4	Median OS: 17.2 months	\$0,000.00
<input type="checkbox"/> Capecitabine, Oxaliplatin and Bevacizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A5	Median OS: 24.6 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FLU/LEO)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A4	Median OS: 19.5 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, Oxaliplatin (FLO/LEO) and Bevacizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A4	Median OS: 22.8 months	\$0,000.00

(56)

References Cited

U.S. PATENT DOCUMENTS

D760,782 S * 7/2016 Kendler D14/492
 D767,615 S * 9/2016 Evin D14/486
 D772,915 S * 11/2016 Evin D14/486
 D773,506 S * 12/2016 Leabman D14/486
 D781,889 S * 3/2017 Wills D14/486
 D788,126 S * 5/2017 Evin D14/485
 D789,947 S * 6/2017 Sun D14/485
 D792,420 S * 7/2017 van den Berg D14/485
 D792,428 S * 7/2017 McGovern D14/485
 D795,891 S * 8/2017 Kohan D14/485
 D810,772 S * 2/2018 Wang D14/486
 D820,292 S * 6/2018 Mander D14/486
 D829,229 S * 9/2018 Durkan D14/486
 D838,287 S * 1/2019 Low D14/486
 D839,289 S * 1/2019 Tuthill D14/486
 D839,902 S * 2/2019 Low D14/486
 D847,170 S * 4/2019 Lirov D14/486
 D854,565 S * 7/2019 McLaughlin D14/486

2006/0085759 A1* 4/2006 Knapheide G06F 3/0482
 715/777
 2011/0072387 A1* 3/2011 Fisher G06F 16/24575
 715/777
 2011/0083074 A1* 4/2011 Jellison, Jr. G06F 3/0481
 715/716
 2013/0212507 A1* 8/2013 Fedoseyeva G06Q 10/00
 715/765
 2015/0143248 A1* 5/2015 Beechuk H04L 67/10
 715/739
 2017/0063912 A1* 3/2017 Muddu G06F 3/0484
 2017/0116560 A1* 4/2017 Wickstrom G06Q 10/06311

OTHER PUBLICATIONS

Nant Health, LLC Registration Statement, May 6, 2016, Securities and Exchange Commission, site visited Mar. 4, 2020: <https://www.sec.gov/Archives/edgar/data/1566469/000119312516581979/d46244ds1.htm> (Year: 2016).*

* cited by examiner

Treatment Options

ALL (10) ENDORSED(8) OMICS-GUIDED (2) CLINICAL TRIALS (7)

Sample Hospital
Order ID: XXXXX

EDIT

Cancer Type: Colon

Pathology: Adenocarcinoma

Stage: Recurrent

Line of Treatment: First Line

Goal of Treatment: Non-curative

Performance Status: 0-Normal Activity (asymptomatic)

MSI Level: Low

K-ras Gene: Mutant

N-ras Gene: Wildtype

BRCA1 Gene: Mutant

ERCC1 Protein: High


TOP01 Protein: High

Select a treatment, and then select Save to link this treatment to the patient. Modify your search using the fields above.


Support
 Opposition
 None

REGIMEN NAME	ENDORSED REGIMEN	OMICS GUIDANCE	OMICS JUSTIFICATION	LEVEL OF EVIDENCE	UNSELECTED OUTCOME (?)	ESTIMATED COST
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of TOP01 has been associated with improved response to Irinotecan.	A4	Median OS: 25.1 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) and Bevacizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of TOP01 has been associated with improved response to Irinotecan.	A4	Median OS: 25.8 months	\$0,000.00
<input type="checkbox"/> Capecitabine	<input checked="" type="checkbox"/>	<input type="checkbox"/>	N/A	A4	Median OS: 15.2 months	\$0,000.00
<input type="checkbox"/> Capecitabine and Bevacizumab	<input checked="" type="checkbox"/>	<input type="checkbox"/>	N/A	B1	Median OS: 16.6 months	\$0,000.00
<input type="checkbox"/> Olaparib	<input type="checkbox"/>	<input checked="" type="checkbox"/>	BRCA1 del in prostate and ovarian cancer (view)	N/A	N/A	\$0,000.00
<input type="checkbox"/> Rucaparib	<input type="checkbox"/>	<input checked="" type="checkbox"/>	BRCA1 del in ovarian cancer (view)	N/A	N/A	\$0,000.00
<input type="checkbox"/> Capecitabine and Oxaliplatin	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A5	Median OS: 17.2 months	\$0,000.00
<input type="checkbox"/> Capecitabine, Oxaliplatin and Bevacizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A5	Median OS: 24.6 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FOLFOX)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A4	Median OS: 19.5 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A4	Median OS: 21.3 months	\$0,000.00

FIG. 1



ORDER ▾



Dr. John Doe | Support

Treatment Options

Sample Hospital

Order ID: XXXXX

Cancer Type: Colon

Performance Status: 0-Normal Activity (asymptomatic)

BRCA1 Gene: Mutant

Pathology: Adenocarcinoma

Adult/Pediatric: Adult

ERCC1 Protein: High

Line of Treatment: First Line

MSI Level: Low

K-ras Gene: Mutant

Goal of Treatment: Non-curative

N-ras Gene: Wildtype

EDIT

Select a treatment, and then select Save to link this treatment to the patient. Modify your search using the fields above.

Support
 Opposition
 None

REGIMEN NAME	ENDORSED REGIMEN	OMICS GUIDANCE	OMICS JUSTIFICATION	LEVEL OF EVIDENCE	UNSELECTED OUTCOME	ESTIMATED COST
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI)			Overexpression of TOP2A has been associated with improved response to Irinotecan.	A4	Median OS: 23.1 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) and Bevacizumab			Overexpression of TOP2A has been associated with improved response to Irinotecan.	A4	Median OS: 25.8 months	\$0,000.00
<input type="checkbox"/> Capecitabine			N/A	A4	Median OS: 13.2 months	\$0,000.00
<input type="checkbox"/> Capecitabine and Bevacizumab			N/A	B1	Median OS: 16.6 months	\$0,000.00
<input type="checkbox"/> Oxiparib			BRCA1 del in prostate and ovarian cancer (view)	N/A	N/A	\$0,000.00
<input type="checkbox"/> Rucaparib			BRCA1 del in ovarian cancer (view)	N/A	N/A	\$0,000.00
<input type="checkbox"/> Capecitabine and Oxaliplatin			Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A5	Median OS: 17.2 months	\$0,000.00
<input type="checkbox"/> Capecitabine, Oxaliplatin and Bevacizumab			Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A5	Median OS: 24.6 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, and Irinotecan (FOLFOX)			Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A4	Median OS: 19.5 months	\$0,000.00
<input type="checkbox"/> Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab			Overexpression of the ERCC1 can cause resistance to platinum-based therapies.	A4	Median OS: 21.3 months	\$0,000.00

FIG. 2